Encision (Encision) Change In Receivables : $-0.09 Mil (TTM As of Dec. 2023)

View and export this data going back to 1996. Start your Free Trial

What is Encision Change In Receivables?

Encision's change in receivables for the quarter that ended in Dec. 2023 was $0.10 Mil. It means Encision's Accounts Receivable declined by $0.10 Mil from Sep. 2023 to Dec. 2023 .

Encision's change in receivables for the fiscal year that ended in Mar. 2023 was $0.03 Mil. It means Encision's Accounts Receivable declined by $0.03 Mil from Mar. 2022 to Mar. 2023 .

Encision's Accounts Receivable for the quarter that ended in Dec. 2023 was $0.92 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Encision's Days Sales Outstanding for the three months ended in Dec. 2023 was 53.24.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Encision's liquidation value for the three months ended in Dec. 2023 was $-0.53 Mil.

Encision Change In Receivables Historical Data

The historical data trend for Encision's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Encision Change In Receivables Chart

Encision Annual Data

Trend

Mar14

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Change In Receivables

Get a 7-Day Free Trial

-0.05

0.10

-0.12

0.16

0.03

Encision Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Change In Receivables	Get a 7-Day Free Trial															0.09	-0.09	0.01	-0.11	0.10

Encision Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.09 Mil.

Encision (OTCPK:ECIA) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Encision's Days Sales Outstanding for the quarter that ended in Dec. 2023 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	0.923	/	1.582	*	91
=	53.24

2. In Ben Graham's calculation of liquidation value, Encision's accounts receivable are only considered to be worth 75% of book value:

Encision's liquidation value for the quarter that ended in Dec. 2023 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	0.099	-	2.094	+	0.75 * 0.923	+	0.5 * 1.554
=	-0.53

Encision Change In Receivables Related Terms

Thank you for viewing the detailed overview of Encision's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Encision (Encision) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Encision Inc (OTCPK:ECIA) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

N/A

Address

6797 Winchester Circle, Boulder, CO, USA, 80301

Website

https://www.encision.com

Encision Inc is a medical device company. The company develops and markets technology that provides unprecedented outcomes and patient safety in minimally-invasive surgery. The company has established and developed AEM (Active Electrode Monitoring) technology and surgical instruments which provides surgeons with the desired tissue effects of cutting and coagulating tissue in laparoscopic procedures while preventing stray electrosurgical energy that can cause complications and even death. The segments of the company are Product and Service. Product designs develops, manufactures and markets patented surgical instruments. Service performs electrical engineering activities for external entities.

Executives

Robert H Fries	director	800 FILLMORE ST, DENVER CO 80206
Peter D Geary	officer: VP of Operations	6797 WINCHESTER CIRCLE, BOULDER CO 80301
Jason E Johnson	officer: VP Sales	17752 WEDGEWOOD LANE, PRIOR LAKE MN 55372
Patrick R Dixon	director	6797 WINCHESTER CIRCLE, BOULDER CO 80301
Gregory J. Trudel	director, officer: CEO	5241 RIMROCK LANE, FORT COLLINS CO 80526
Brian J Jackman	director	6797 WINCHESTER CIRCLE, SUITE 100, BOULDER CO 80301
Von Der Lippe Paul	director	6797 WINCHESTER CIRCLE, BOULDER CO 80301
Denise Baker	director	6797 WINCHESTER CIRCLE, BOULDER X1 80301
Vern D Kornelsen	director, 10 percent owner	4605 S. DENICE DR, ENGLEWOOD CO 80111
Partners Lllp Cmed	10 percent owner
Patrick W Pace	director	3701 SOARING EAGLE, AUSTIN TX 78746
Michael Biggs	officer: VP Engineering	6797 WINCHESTER CIRCLE, BOULDER CO 80301
Brad Greathouse	officer: VP RA/QA	6797 WINCHESTER CIRCLE, BOULDER CO 80301
Valerie Ray	officer: VP of Operations	6797 WINCHESTER CIRCLE, BOULDER CO 80301
David W Newton	director, officer: VP Technology	8099 NORTH 63RD STREET, LONGMONT CO 80503